Wednesday, August 15, 2018
 
 
Company News: Page (1) of 1 - 07/19/18 Email this story to a friend. email article Print this page (Article printing at MyDmn.com).print page facebook
Nasdaq Welcomes Rubius Therapeutics, Inc. (Nasdaq: RUBY) to the Nasdaq Stock Market

(July 19, 2018)

NEW YORK, July 19, 2018 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a biotechnology company pioneering the development of a new class of ready-to-use cellular therapies, rang the Nasdaq Stock Market Opening Bell in Times Square today in celebration of its initial public offering (IPO) on The Nasdaq Stock Market.

Rubius Therapeutics is pioneering a new era of medicines called Red Cell Therapeutics™. The company’s proprietary RED PLATFORM™ was designed to genetically engineer and culture Red Cell Therapeutics that are selective, potent and ready-to-use cellular therapies for the potential treatment of several diseases across multiple therapeutic areas. The company plans to file its first Investigational New Drug application for RTX-134 in phenylketonuria, a rare disease that affects 13,000 people in the U.S., during the first quarter of 2019, with additional INDs in 2019, 2020 and beyond.

“Rubius Therapeutics is advancing the development of Red Cell Therapeutics with the potential to treat patients with rare diseases, cancer and autoimmune diseases,” said Pablo J. Cagnoni, M.D., Chief Executive Officer. “We are honored to join the Nasdaq family as we advance our vision of providing life-changing and life-saving benefits to patients.”

“Rubius Therapeutics has been pioneering the creation of cellular therapies for patients,” said Nelson Griggs, President of the Nasdaq Stock Exchange. “We are excited to welcome Rubius and its experienced leadership team to join Nasdaq alongside with the world’s leading biotechnology and pharmaceutical companies as they continue their journey as a public company.”

The information contained above is provided for informational and educational purposes only, and nothing contained herein should be construed as investment advice, either on behalf of a particular security or an overall investment strategy. Information about the company is provided by the company or comes from the company’s public filings and is not independently verified by Nasdaq. Neither Nasdaq nor any of its affiliates makes any recommendation to buy or sell any security or any representation about the financial condition of any company. Statements regarding Nasdaq-listed companies are not guarantees of future performance. Actual results may differ materially from those expressed or implied. Past performance is not indicative of future results. Investors should undertake their own due diligence and carefully evaluate companies before investing. ADVICE FROM A SECURITIES PROFESSIONAL IS STRONGLY ADVISED.

About Nasdaq

Nasdaq (Nasdaq:NDAQ) is a leading global provider of trading, clearing, exchange technology, listing, information and public company services. Through its diverse portfolio of solutions, Nasdaq enables customers to plan, optimize and execute their business vision with confidence, using proven technologies that provide transparency and insight for navigating today’s global capital markets. As the creator of the world’s first electronic stock market, its technology powers more than 90 marketplaces in 50 countries, and 1 in 10 of the world’s securities transactions. Nasdaq is home to approximately 3,900 total listings with a market value of approximately $12 trillion. To learn more, visit: http://business.nasdaq.com

Media Relations Contact:

- NDAQG -

A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/4f510755-220f-4a53-b928-aa04be5f4dc2

 



Page: 1


Related Keywords:
Related Sites: DMN Newswire ,   HTN - Health Technology Net
Related Newsletter: Tutorial Finder ,   Review Seeker ,   DMN Newswire Newsletter
 
 
 
 
 
 
 
Seniors

Drugs
  • Neurovascular Devices Market High Revenue at USD 24,650 mn by 2023 | Therapeutic Application Hemorrhagic & Ischemic Strokes | Worldwide Segmentation by MRFR
  • New Report Identifies Unique Challenges for LGBT Community Facing Alzheimer's and Other Dementias
  • The Buck Institute, Insilico Medicine, and Juvenescence Found Napa Therapeutics to Develop Drugs to Impede Age-Related Disease,
  • The Buck Institute, Insilico Medicine, and Juvenescence Found Napa Therapeutics to Develop Drugs to Impede Age-Related Disease
  • Global Spinal Fusion Devices Market Expected to Reach USD 6.8 Billion By 2024: Zion Market Research

    Cancer
  • Biotest AG: Cytotect(R) CP prevents transmission of Cytomegalovirus (CMV) to the unborn baby in pregnant women who are infected with CMV for the first time
  • ViewRay Announces Pricing of Public Offering of Common Stock
  • Global Cancer Monoclonal Antibody Partnering Terms and Agreements 2012-2018: Deal trends, players, financials and forecasts
  • CASI Pharmaceuticals Announces Second Quarter And First Half 2018 Financial And Business Results
  • Citius Announces Closing of $10.0 Million Underwritten Offering Priced At-the-Market
  •  
     
     
     
     
     





    Our Privacy Policy --- About The Health Technology - Contact Us - Advertise With Us - Privacy Guidelines